Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.

Haematologica·2021

Same author

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.

British journal of haematology·2021

Same author

Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma.

Blood cancer journal·2021

Same author

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.

The Lancet. Oncology·2021

Same author

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML.

Blood·2021

Same author

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

The New England journal of medicine·2021

Search research articles

Related Experiment Video

Updated: Jan 5, 2026

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

CMV-specific immunotherapy.

Hermann Einsele¹, Holger Hebart

¹Medizinische Klinik und Poliklinik, Abteilung II, Eberhard-Karls-Universität Tübingen, Tübingen, Germany. hermann.einsele@med.uni-tuebingen.de

Human Immunology

|June 3, 2004

Summary

Immunotherapy using T cells shows promise for restoring immunity against cytomegalovirus (CMV) infections in immunocompromised patients. Further research into adoptive immunotherapy and genetically modified T cells aims to improve treatment safety and efficacy.

Area of Science:

Immunobiology
Immunocompromised Hosts
Viral Infections

Background:

Understanding of immunobiology in immunocompromised hosts has advanced.
Animal and human studies provide rationale for T cell immunotherapy.
Cytomegalovirus (CMV) infection poses significant risks to immunocompromised individuals.

Purpose of the Study:

Investigate immunotherapy with alphabeta+ T cells to restore protective immunity against CMV.
Explore adoptive immunotherapy with various immunoeffector cells for improved viral control.
Evaluate the potential of genetically modified T cells for enhanced immunotherapy.

Main Methods:

Utilizing insights from animal models and human studies.
Clinical evaluation of genetically modified T cells.

More Related Videos

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Related Experiment Videos

Last Updated: Jan 5, 2026

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Focus on restoring immune responses essential for CMV protection.

Main Results:

Early-stage studies suggest cellular immunotherapy is a promising area.
Genetically modified T cells show potential for improved safety and efficacy.
Identified challenges in implementing cellular immunotherapy.

Conclusions:

Cellular immunotherapy holds significant potential for treating viral infections in immunocompromised hosts.
Future research directions include exploring different cell populations and genetic modifications.
Overcoming technical challenges is crucial for successful clinical application.